Home / Publications / The Antidote - Spring 2014

The Antidote - Spring 2014

Taking a look at "pharmerging" markets and the resurgence in UK biotech IPOs

01/05/2014

We can barely keep up with what is, or is speculated to be, happening in the sector with big pharma. In this edition, we comment on some of the M&A activity and await with interest what may occur over the next weeks and months.

We also look at why the Far East continues to hold so much promise for the sector, particularly in China and Singapore and we look at what may be the start of a resurgence for UK biotech IPOs.

As you may also be aware, CMS today merged with leading Scottish law firm, Dundas & Wilson, and we are delighted to welcome Carina Healy as a member of our core Lifesciences group. Carina brings a wealth of experience to the group and we very much look forward to introducing you to Carina over the coming months.

Guide
The Antidote
Download
PDF 1.2 MB

Authors

Portrait ofOmar Qureshi
Omar Qureshi
Partner
London
Portrait ofNick Beckett
Nick Beckett
Managing Partner
Beijing
Portrait ofSarah Hanson
Sarah Hanson
Partner
London
Portrait ofShuna Mason
Shuna Mason
Partner
London
Portrait ofCarina Healy
Carina Healy
Partner
Glasgow
Portrait ofJames Parkes
James Parkes
Partner
London
Portrait ofSam Dames
Sam Dames
Partner
London
Sandra Rafferty
John Markham
David Butts
Caroline Hobson
Show more Show less